Avalyn Pharma (NASDAQ:AVLN) Trading Up 6.8% - Time to Buy?

Key Points

• Avalyn Pharma shares rose 6.8% to about $35.86, giving the clinical-stage biopharmaceutical company a market capitalization of approximately $1.56 billion.
• Analyst sentiment is generally positive, with a consensus rating of “Moderate Buy” and an average price target of $60.00; targets range from $52.00 to $80.00.
• Avalyn reported a quarterly loss of $0.98 per share, narrower than the expected $1.03 loss. Institutional investors, including Montanova Capital and Braidwell, also recently established sizable positions.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) shares rose 6.8% during trading on Monday . The company traded as high as $36.16 and last traded at $35.86. 248,034 shares traded hands during mid-day trading, a decline of 21% from the average daily volume of 312,304 shares. The stock had previously closed at $33.57.

Wall Street Analyst Weigh In

AVLN has been the topic of several recent analyst reports. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a "buy" rating and a $52.00 price objective on the stock. Morgan Stanley lifted their price target on Avalyn Pharma from $53.00 to $57.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th. Zacks Research raised Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Wall Street Zen upgraded Avalyn Pharma from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Guggenheim began coverage on Avalyn Pharma in a research report on Monday, May 25th. They issued a "buy" rating and a $80.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Avalyn Pharma presently has a consensus rating of "Moderate Buy" and a consensus price target of $60.00.

Avalyn Pharma Trading Up 4.8%

The company has a market cap of $1.56 billion and a price-to-earnings ratio of -1.54. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The stock's 50 day moving average price is $32.79.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.05. On average, equities research analysts predict that Avalyn Pharma Inc. will post -3.81 EPS for the current year.

Institutional Investors Weigh In On Avalyn Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma in the second quarter valued at about $1,321,000. Montanova Capital LLC bought a new stake in Avalyn Pharma in the 2nd quarter valued at about $82,402,000. Braidwell LP bought a new stake in Avalyn Pharma in the 2nd quarter valued at about $26,382,000. Finally, California State Teachers Retirement System acquired a new position in shares of Avalyn Pharma during the 2nd quarter worth approximately $236,000.

Avalyn Pharma Company Profile

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn's lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.